Last10K.com

Amphastar Pharmaceuticals, Inc. (AMPH) SEC Filing 10-Q Quarterly report for the period ending Saturday, September 30, 2017

Amphastar Pharmaceuticals, Inc.

CIK: 1297184 Ticker: AMPH

EXHIBIT 99.1

 

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2017

 

Reports Net Revenues of $57.9 Million for the Three Months Ended September 30, 2017

 

RANCHO CUCAMONGA, CA –  November 8, 2017 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended September 30, 2017.

 

Third Quarter Highlights

 

·

Net revenues of $57.9 million for the third quarter

·

GAAP net income of $0.2 million, or $0.00 per diluted share, for the third quarter

·

Adjusted non-GAAP net income of $3.5 million, or $0.07 per diluted share, for the third quarter

 

Dr. Jack Zhang, Amphastar’s CEO, commented: “The third quarter was a successful one for Amphastar with approvals of both sodium bicarbonate and neostigmine. Approvals like these will help us diversify our sales base.”

   

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

 

September 30, 

 

September 30, 

 

 

 

2017

 

2016

 

2017

 

2016

 

 

 

(in thousands, except per share data)

 

Net revenues

    

$

57,916

    

$

64,223

    

$

179,773

    

$

191,622

 

GAAP net income

 

$

175

 

$

3,890

 

$

3,040

 

$

13,274

 

Adjusted non-GAAP net income*

 

$

3,495

 

$

6,648

 

$

13,399

 

$

22,557

 

GAAP diluted EPS

 

$

0.00

 

$

0.08

 

$

0.06

 

$

0.29

 

Adjusted non-GAAP diluted EPS*

 

$

0.07

 

$

0.14

 

$

0.28

 

$

0.49

 


The following information was filed by Amphastar Pharmaceuticals, Inc. (AMPH) on Wednesday, November 8, 2017 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Amphastar Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Amphastar Pharmaceuticals, Inc..

Continue

Assess how Amphastar Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Amphastar Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (parenthetical)
Condensed Consolidated Statements Of Cash Flows
Condensed Consolidated Statements Of Comprehensive Income (loss)
Condensed Consolidated Statements Of Operations
Business Acquisition (acquisition Of Merck's Api Manufacturing Business) (details)
Business Acquisition (narrative) (details)
Business Acquisitions
Business Acquisitions (tables)
Commitments And Contingencies
Commitments And Contingencies (collaboration Agreement) (details)
Commitments And Contingencies (operating Lease Agreements) (details)
Commitments And Contingencies (purchase Commitments) (details)
Commitments And Contingencies (supply Agreement With Mannkind Corporation) (details)
Customer And Supplier Concentration
Customer And Supplier Concentration (details)
Customer And Supplier Concentration (tables)
Debt
Debt (narrative) (details)
Debt (schedule Of Debt) (details)
Debt (tables)
Employee Benefits
Employee Benefits (details)
Fair Value Measurements
General
Goodwill And Intangible Assets
Goodwill And Intangible Assets (summary Of Changes In The Carrying Amount Of Goodwill) (details)
Goodwill And Intangible Assets (summary Of Intangible Assets) (details)
Goodwill And Intangible Assets (tables)
Income Per Share
Income Per Share (calculation Of Basic And Diluted Net Income (loss) Per Share) (details)
Income Per Share (narrative) (details)
Income Per Share (tables)
Income Taxes
Income Taxes (summary Of Income Tax Provision) (details)
Income Taxes (tables)
Income Taxes (valuation Allowance - Narrative) (details)
Inventories
Inventories (details)
Inventories (tables)
Litigation
Litigation (details)
Property, Plant, And Equipment
Property, Plant, And Equipment (summary Of Property, Plant, And Equipment) (details)
Property, Plant, And Equipment (tables)
Revenue Recognition
Revenue Recognition (analysis Of Product Return Liability) (details)
Revenue Recognition (analysis Of The Chargeback Provision) (details)
Revenue Recognition (tables)
Segment Reporting
Segment Reporting (selected Financial Information By Reporting Segment) (details)
Segment Reporting (summary Of Net Revenues By Product Segment) (details)
Segment Reporting (summary Of Revenues And Long-lived Assets By Geographic Region) (details)
Segment Reporting (tables)
Stockholders' Equity
Stockholders' Equity (2014 Employee Stock Purchase Plan) (details)
Stockholders' Equity (equity Awards To Consultants And Advisory Board Members) (details)
Stockholders' Equity (information Relating To Option Grants And Exercises) (details)
Stockholders' Equity (information Relating To Rsu Grants And Deliveries) (details)
Stockholders' Equity (key Assumptions Used In Determining Fair Value Of Options Granted) (details)
Stockholders' Equity (restricted Stock Units) (details)
Stockholders' Equity (share Buyback Program) (details)
Stockholders' Equity (share-based Compensation Expense Included In The Statement Of Operations) (details)
Stockholders' Equity (summary Of Nonvested Options) (details)
Stockholders' Equity (summary Of Option Activity) (details)
Stockholders' Equity (summary Of The Changes In Stockholders' Equity) (details)
Stockholders' Equity (tables)
Stockholders' Equity (the 2015 Equity Incentive Plan) (details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (details)
Summary Of Significant Accounting Policies (policies)
Ticker: AMPH
CIK: 1297184
Form Type: 10-Q Quarterly Report
Accession Number: 0001297184-17-000035
Submitted to the SEC: Wed Nov 08 2017 8:27:48 PM EST
Accepted by the SEC: Thu Nov 09 2017
Period: Saturday, September 30, 2017
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/amph/0001297184-17-000035.htm